Format

Send to

Choose Destination
Mol Immunol. 1994 Dec;31(17):1353-63.

Antigenicity and immunogenicity of P30-derived peptides in experimental models of toxoplasmosis.

Author information

1
Centre d'Immunologie et de Biologie Parasitaire, INSERM U167, CNRS 624, Institut Pasteur de Lille, France.

Abstract

P30, also referred to as SAG-1, is now recognized as a major Toxoplasma gondii antigen potentially important for both diagnosis and immunoprophylaxis of toxoplasmosis. By using predictive algorithms, five synthetic peptides (48-67, 82-102, 213-230, 238-256 and 279-285) derived from P30, were investigated for B- and T-cell determinants in mouse and rat experimental models. Antibody recognition appeared more broadly distributed along the P30 sequence, whereas T-cell recognition was mainly targeted on the 238-256 peptide. In the absence of any carrier protein, this peptide induced a B- and T-cell immune response independent of the route of immunization (oral route or subcutaneous injection). This peptide (238-256) induced multiple antibody isotypes. In contrast with the 238-256 peptide, the 48-67 peptide, either free or in the form of a multiple antigenic peptide (MAP) construct or the 279-295 peptide, elicited antibodies associated with a TH2 response. This study reports for the first time the analysis of the antigenic and immunogenic properties of P30-derived peptides and are potentially useful for vaccinal strategies incorporating the P30 Toxoplasma gondii antigen.

PMID:
7997247
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center